The sex hormone profile of male patients with breast cancer

Nirmul, D.; Pegoraro, R.J.; Jialal, Ishwarlal; Naidoo, C; Joubert, S. M.

doi:10.1038/bjc.1983.208

Cited by 42 publications

(19 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, this suppression was inadequate to produce a therapeutic response. Basal oestradiol levels in our series were in the same range as reported by Nirmul et al (1982). The patients were not intrinsically resistant to endocrine therapy, since 3 out of 4 responded to tamoxifen.…”

Section: Resultssupporting

confidence: 72%

Role of aminoglutethimide in male breast cancer

Harris¹,

Dowsett²,

Stuart-Harris³

et al. 1987

Br J Cancer

View full text Add to dashboard Cite

Summary Five men with advanced breast cancer were treated with aminoglutethimide (AG) plus replacement dose hydrocortisone. None of the 4 patients with intact testes responded, although 3 did so subsequently to tamoxifen. The previously orchidetomised patient responded to amminoglutethimide for 14 months. Oestrone and oestradiol were suppressed by AG in all patients, but not to the levels achieved by orchidectomy. AG produced substantial further oestrogen suppression in the orchidectomised patient and should only be used after orchidectomy.Breast cancer in males is an uncommon disease. It accounts for 1 % of all breast cancers and is frequently sensitive to hormone manipulation (Ribeiro, 1985). Breast cancer in men presents at a more advanced stage and in older age groups compared with women, but when matched for these prognostic variables, survival is similar (Scheike, 1982). Because of these clinical features, systemic endocrine therapy is commonly combined with local treatment, castration being a standard first line endocrine approach.Recently, aminoglutethimide has been shown to be effective in postmenopausal women with breast cancer, the main mechanism of action being inhibition of the peripheral conversion of androgens to oestrogens by aromatase (Harris et al., 1982a;1983a). In men, three quarters of oestradiol produced results from peripheral aromatisation of testosterone (Epstein et al., 1966;Longcope et al., 1969;Wu et al., 1982). Thus aminoglutethimide could potentially be useful either to avoid castration or as a second line endocrine therapy to suppress residual oestrogen production via androgens from the adrenal after castration. Patients and methodsFive men with advanced breast cancer were treated with aminoglutethimide and replacement dose hydrocortisone (20mg twice daily). Four patients received the conventional dose of aminoglutethimide, 250 mg four times daily, and one received 125mg twice daily.Plasma samples were taken before treatment and at 2 weekly intervals for measurement of oestrone, Correspondence: A.L. Harris.

show abstract

Section: Resultssupporting

confidence: 72%

Role of aminoglutethimide in male breast cancer

Harris¹,

Dowsett²,

Stuart-Harris³

et al. 1987

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…In a previous report (Ribeiro, 1977) (1973) but not with other reports (Dao et al, 1973, Calabresi et al, 1976Nirmul et al, 1982). The reasons for the difference may be in the methodology, the paucity of patients, the choice of controls, or even due to ethnic variations.…”

Section: Discussionmentioning

confidence: 96%

Male breast carcinoma--a review of 301 cases from the Christie Hospital & Holt Radium Institute, Manchester

Ribeiro¹

1985

Br J Cancer

123

View full text Add to dashboard Cite

“…[3] In Manchester, England, a 0.7 percent inci¬dence was reported, unchanged from the previous report in 1977. [19] Higher rates are reported in blacks, including 2.4 percent among West Africans in the report by Ajayi et al [4] and a three percent incidence in black males by Nirmul et al [5] An unusually high incidence is reported in Zambia, where 15 percent of all breast cancer is in males. [6] In Virginia, there is a disproportionately higher percentage of male breast cancer in black males (24 percent) in comparison with black females (16 percent).…”

Section: Disucssionmentioning

confidence: 92%

Male Breast Cancer – Actuality of Our Days

Iordache

Unc

Liliana

et al. 2015

ARS Medica Tomitana

View full text Add to dashboard Cite

Coming from a female pacient's point of view, breast cancer is a hard to bare diagnosis. But what about the male patient? Although is very rare, male breast cancer does exist, and in the majority of cases, it is diagnosed in a very advanced stage with minimal curative posibilities. The critical medical education in our country along with the absence of a well structured national screening program are both provocative factors for the existence of this kind of disease. This work is based upon a retrospective study on 976 patients (919 females and 57 males) who were diagnosed and requiring medical treatment for mammary neoplasm between 2008-2013 under the auspices of the Surgery Clinic inside the Clinical and Emergency District Hospital of Constanta. From all the patient's anamnestic common elements like smoking, liver diseases, stress, radiation exposure, family antecedents that are related to the actual suffering, we can draw a latiogeneral instalation pattern of cancer. This study is meant to point out the similarities and especially the differences between the specialised bibliography and the collected information from the existing pathology concerning the age incidence, the type of neo formation, the location, histo-pathologic diagnosis, the types of surgical procedures and also to make evident the causes producing delay in starting the surgical treatment with visible consequential effects on both surviving and the quality of life.

show abstract

The sex hormone profile of male patients with breast cancer

Cited by 42 publications

References 11 publications

Role of aminoglutethimide in male breast cancer

Role of aminoglutethimide in male breast cancer

Male breast carcinoma--a review of 301 cases from the Christie Hospital & Holt Radium Institute, Manchester

Male Breast Cancer – Actuality of Our Days

Contact Info

Product

Resources

About